Oncosec Medical Incorporated announced published data in Clinical Cancer Research, linked here, that demonstrated its lead product candidate, TAVO™ (interleukin-12 or "IL-12" plasmid), in combination with the anti-PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab), produced a 41% overall response rate (ORR), with 36% complete response in a Phase 2, single arm study evaluating patients with metastatic melanoma selected to be anti-PD-1 checkpoint resistant. In the trial, responses were observed in nine of 22 evaluable patients, for an objective response rate of 41%. 36% of patients experienced a complete response. Median progression-free survival was 5.6 months, with median overall survival not yet reached after a median follow-up of 19.6 months. Grade 3 or higher adverse events were limited and included pain, chills, sweat and cellulitis, as well as certain toxicities usually observed with immune checkpoint inhibitors such as pembrolizumab. The KEYNOTE-695 study is a pivotal, global, open-label trial of TAVO in combination with KEYTRUDA® in patients with anti-PD-1 checkpoint resistant metastatic melanoma. TAVO has been designated fast track and orphan drug status by the U.S. FDA and following completion of the KEYNOTE-695 study OncoSec intends to file for accelerated U.S. approval.